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Background: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder involving
motor and cognitive dysfunction. Currently, there is no effective treatment either for symptomatic relief or
disease modification. This relates, in part, to a lack of knowledge of the underlying neurochemical
abnormalities, including cholinergic receptor status in the basal ganglia.
Aim: To measure muscarinic M2 and M4 receptors in the basal ganglia in PSP.
Methods: The muscarinic M2 (presynaptic) and M4 (postsynaptic) receptors in the striatum, pallidum and
adjacent insular cortex were autoradiographically measured in pathologically confirmed cases of PSP
(n = 18), and compared with cases of Lewy body dementias (LBDs; n = 45), Alzheimer’s disease (AD; n = 39)
and controls (n = 50).
Results: In cases of PSP, there was a reduction in M2 and M4 receptors in the posterior caudate and putamen
compared to controls, but no significant changes in the pallidum. Cases with AD showed lower M2 receptors
in the posterior striatum. Groups with LBD and AD showed higher M2 binding in the insular cortex compared
with controls.
Conclusions: The results suggest loss of posterior striatal cholinergic interneurones in PSP, and reduction in
medium spiny projection neurones bearing M4 receptors. These results should be taken in the context of more
widespread pathology in PSP, but may have implications for future trials of cholinergic treatments.
P
rogressive supranuclear palsy (PSP) was first described by
Steele et al in 19641, as a disease causing vertical gaze and
pseudobulbar palsy, early falls, parkinsonism and demen-
tia. Patients typically present in their 60s and the average time
from symptom-onset to death ranges from 5 to 8.6 years.2–5
Neuropathological hallmarks of PSP include neurofibrillar
tangles, neuropil threads and tufted astrocytes which are found
predominantly within the basal ganglia, midbrain, pontine
reticular formations and to a lesser extent, the thalamus.6 The
pathological inclusions comprise insoluble aggregates of four-
repeat t phosphoprotein. The basal ganglia, in particular the
striatum (caudate and putamen) and its connections, are
involved in motor and cognitive aspects of PSP.
Neurochemical abnormalities are found within the dopami-
nergic, cholinergic and possibly GABAergic systems.7 8
Cholinergic deficits are thought to be responsible for the early
postural instability and cognitive impairment commonly found
in PSP. Trials of a muscarinic M1/M2 cholinergic agonist9 and
cholinesterase inhibitors10 11 have, however, failed to show
improvement in motor function, quality of life or cognitive
impairment.
In cases of PSP, there are abnormalities within the
cholinergic system based on pathology in known cholinergic
nuclei and reduced markers for the synthesis and release of
acetylcholine (ACh) but there is a dearth of knowledge about
the status of cholinergic receptors.
M1, M2 and M4 receptors are the predominant muscarinic
receptors found in the striatum. We have recently demon-
strated no significant difference in the M1 receptors in the
striatum of patients with PSP compared with controls.12 This
suggests preservation of the medium spiny neurones bearing
these receptors, which are predominantly involved in the
indirect pathway (projecting to the external globus pallidus
(GPe)). M2 receptors are found presynaptically on striatal
cholinergic interneurones, and also on corticostriatal and
thalamostriatal afferents. Their activation inhibits the release
of neurotransmitter and, therefore, through the cholinergic
interneurones they provide a negative feedback mechanism for
the release of ACh. M4 receptors are predominantly located on
the postsynaptic membranes of striatal medium spiny projec-
tion neurones expressing D1 receptors, which form part of the
direct pathway, projecting to the internal globus pallidus (GPi).
When activated, M2 and M4 receptors inhibit adenylyl cyclase
by a complex cascade of events through a G protein.
We aimed to define the status of the muscarinic M2 and M4
receptors in the striatum and pallidum to provide a more
detailed understanding of the basal ganglia cholinergic
neurochemistry of PSP. Cases with Lewy body dementia
(LBD, a group comprising dementia with Lewy bodies (DLB)
and Parkinson’s disease with dementia (PDD)) and Alzheimer’s
disease (AD) were chosen as disease controls as they share
some cliniconeurochemical similarities with PSP. Notably,
cholinesterase inhibitors improve cognitive and neuropsychia-
tric symptoms in patients with DLB, PDD and AD13–15 but are
not beneficial in PSP, showing no demonstrable improvement
in cognition and a possibly detrimental effect on motor
symptoms.11 16
METHODS
Subjects
Eighteen pathologically confirmed cases of PSP, from which
anterior striatal sections were available in 16 and posterior in
12, were acquired from the Newcastle Brain Bank, Newcastle
upon Tyne, UK and the Sara Koe PSP Research Centre, Institute
of Neurology, University College London, London, UK. They
were compared with age-matched controls (n = 50, 27 anterior
striatum, 33 posterior striatum) and patients with LBD (n = 45
Abbreviations: ACh, acetylcholine; AD, Alzheimer’s disease; DLB,
dementia with Lewy bodies; GPe, external globus pallidus; GPi, internal
globus pallidus; LBD, Lewy body dementia; PD, Parkinson’s disease; PDD,
Parkinson’s disease with dementia; PM, post mortem; PSP, progressive
supranuclear palsy
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(27 DLB and 18 PDD), 37 anterior striatum, 34 posterior
striatum) and AD (n = 39, 27 anterior striatum, 27 posterior
striatum). Clinical information for patients with PSP was
obtained where possible, through a retrospective notes review.
Patients with DLB, PDD and AD were prospectively assessed
annually. Table 1 shows the patient demographics. One patient
with LBD was taking a cholinesterase inhibitor, and three were
taking anticholinergics. None of the groups with PSP or AD had
taken cholinergic drugs. There were no significant intergroup
differences in postmortem delay. Table 2 gives a summary of
the pathological findings in cases of PSP in relevant areas.
Consent for brain donation was obtained either from the
patient, or/and the next of kin, in accordance with the local
research ethics committee (Newcastle and North Tyneside) and
the London Multi-Centre Research Ethics Committee.
Tissue preparation
The right cerebral hemisphere was fixed and used for
pathological diagnosis and the left cerebral hemisphere was
sliced into 1 cm thick coronal blocks and rapidly frozen in
liquid Arcton cooled over liquid nitrogen and stored at 270 C˚.
Cases acquired in the past 3 years have been quickly frozen on
copper plates maintained at 280 C˚. There is no difference in
tissue quality between the two freezing methods. Frozen tissue
sections containing basal ganglia at a level including the
striatum, globus pallidus and insular cortex were subdissected.
Anterior striatum was up to, and including, coronal level 13,
and posterior from coronal level 14, that is rostral and caudal of
the anterior commissure.17 For autoradiography, 20 mm cryostat
sections were cut and dried onto Vectabond-coated (Vector
labs, Peterborough, UK) slides before storage at –70 C˚. Prior to
assay, slides were taken to room temperature and air dried for
1–2 h.
Autoradiographic ligand binding assays
The total and selective binding was determined in triplicate
contiguous sections and non-specific binding established in one
section by the addition of 2 mM atropine. At room temperature,
sections were prewashed in a buffer (10 mM KH2PO4, 10 mM
Na2HPO4 pH 7.4) for 15 min to remove any endogenous ligand,
for example acetylcholine or residual drugs. M2 and M4
combined receptor density was measured using 3H AFDX 384,
which labels both receptors (total binding) and, in adjacent
sections, selectively blocking M4 binding with dicyclomine.
After prewashing with a buffer, 4.8 nM 3H AFDX 384 alone,
with dicyclomine (10 nM) or with atropine was added and
incubated for 1 h at room temperature. Sections were washed
in the buffer two times for 2 min before being dipped in ice-
cold water, dried and apposed to tritium-sensitive hyperfilm
(Amersham, GE Healthcare, Little Chalfont, UK) for 7 weeks.
Developing and analysis
Films were developed after warming to room temperature (2 h)
before development using 500 ml D19 for 5 min, stopped using
500 ml 1% aqueous acetic acid for 1 min, fixed using 500 ml
25% Unifix (H.A. West, Gateshead, UK) for 6 min and washed
for 20 min in running water. Films were dried and binding was
assessed by comparison to 3H autoradiographic microscale
standards (Amersham) using MCID M5+ image analysis
(Imaging Research GE Healthcare, Interfocus, Linton, UK) to
give binding in fmols/mg. The specific binding for combined M2
and M4 receptors was calculated by subtracting the non-
specific binding from the total. Similarly, M2 was determined
by subtracting non-specific binding from total plus dicyclo-
mine. M4 was then determined by taking the M2-binding value
away from the total.
Statistical analysis
Statistical analysis was performed using MINITAB V.13. For the
neurochemical data, results were compared between PSP,
controls, LBD and AD. Where possible, data were correlated
with clinical measures. To ensure a normal distribution, results
were logged before analysis and the means were antilogged.
Results are presented as geometric means and SD. Statistical
tests included one-way analysis of variance between disease
groups, with post hoc analysis using Tukey’s pairwise compar-
isons where indicated. Regression analysis was used to explore
Table 1 Demographic details of study groups
Control (n = 50) PSP (n = 18) LBD (n = 45) AD (n = 39)
Mean (SD) age at death (years) 79.6 (8.8) 76.0 (8.2) 79.3 (7.0) 83.9 (6.1)*
Male/Female 17/33 11/7 25/20 19/20
Mean (SD), disease duration (years) – 6.1 (3.5) 7.8 (5.6) 5.5 (2.9)
PM delay (hours) 38.4 (22.5) 45.7 (23.4) 37.4 (21.2) 44.9 (23.8)
AD, Alzheimer’s disease; LBD, Lewy body dementia; PSP, progressive supranuclear palsy; PM, post mortem.
*AD age higher vs controls and LBD p,0.05, and vs PSP p,0.01.
Table 2 Range of progressive supranuclear palsy
pathology found in 18 cases
Caudate (anterior
and posterior
levels)
Putamen (anterior
and posterior
levels) GPe GPi
NL NFT NL NFT NL NFT NL NFT
0/+ ++ to
+++
+ + to ++ +++ ++ to
+++
++ ++ to
+++
+= mild, ++ = moderate, +++ = severely affected. GPe, external globus
pallidus; GPi, internal globus pallidus; NL, neuronal loss; NFT,
neurofibrillary tangles.
Table 3 M2 receptor binding in the anterior and posterior
striatum
M2 anterior
M2 posterior Control PSP LBD AD
Caudate 32.5 (0.1) 29.7 (0.1) 36.4 (0.1) 36.9 (0.2)
28.7 (0.1) 18.0 (0.2)` 25.2 (0.1)1 22.1 (0.2)*
Putamen 32.4 (0.1) 33.0 (0.1) 38.6 (0.1) 38.6 (0.2)
33.1 (0.1) 23.0 (0.1) 30.0 (0.1) 25.4 (0.2)`
GPe 4.9 (0.3) 5.0 (0.3) 4.4 (0.3) 5.2 (0.3)
2.9 (0.4) 2.8 (0.1) 3.6 (0.2) 3.0 (0.5)
GPi 2.3 (0.4) 3.9 (0.2) 3.7 (0.2) 2.6 (0.5)
Insular cortex 14.0 (0.1) 17.1 (0.2) 19.7 (0.2) 18.8 (0.2)*
15.6 (0.1) 11.4 (0.2)* 15.7 (0.1)1 13.5 (0.2)
AD, Alzheimer’s disease; GPe, external globus pallidus; GPi, internal globus
pallidus; LBD, Lewy body dementia; PSP, progressive supranuclear palsy.
Values in bold indicate M2 receptor binding in the anterior striatum.
Values expressed as geometric means (SD) in fmol/mg.
*Disease vs control, p,0.05.
Disease vs control, p,0.01.
`Disease vs control, p,0.001.
1PSP vs LBD, p,0.05.
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potential correlations between clinical variables, demographics
and neurochemical data.
RESULTS
Progressive supranuclear palsy
M2 receptor binding
Table 3 and figs 1 and 2 show the results for M2 receptor
binding. M2 binding in controls was highest in the caudate and
putamen, and lowest in the pallidum. A striatal rostrocaudal
reduction was seen in M2 binding. This gradient was more
marked in the group with PSP. The density of M2 receptor
binding was significantly reduced in the posterior caudate
(–37%, p,0.001) and putamen (–31%, p,0.01) in PSP
compared with controls. In the anterior striatum, there was
no significant change in M2 binding. There was no significant
difference in M2 binding in either the internal or external
globus pallidus. Reduced M2 binding was seen in the posterior
insular cortex compared with controls (–27%, p,0.05).
M4 receptor binding
Table 4 and figs 1 and 2 show the results for M4 receptor
binding. Highest binding in controls was again in the striatum
with low binding in the pallidum. There was a rostrocaudal
reduction in M4 receptors in PSP, which was not evident in the
other groups. The posterior striatum showed significantly lower
M4 binding than controls (caudate reduced by 51%, p,0.001,
and putamen by 36%, p,0.05). M4 binding in the caudate was
also significantly lower than in groups with LBD and AD and
the M4 binding in the putamen was lower than in groups with
LBD. GPi M4 binding was increased in those with PSP relative
to all groups, but this did not reach statistical significance. M4
receptor binding in the insular cortex was lower in cases of PSP
than controls (–33%, p,0.05) and LBD (–44%, p,0.001).
Lewy body dementias
M2 receptor binding in the striatum and pallidum was normal.
In the anterior insular cortex, M2 binding was increased
compared with controls (+40%, p,0.01), and in the posterior
insular cortex M2 binding was increased compared with PSP
(+38%, p,0.05). There was a trend towards higher M4 binding
in the GPe in LBD compared with controls although this did not
reach statistical significance.
Alzheimer’s disease
There was a decrease in M2 binding in the posterior striatum of
23%, caudate (p,0.05) and putamen (p,0.001). There was a
significant increase in M2 binding in the anterior insular cortex
(+34%, p,0.05). There was a trend towards reduced M4
binding in the striatum but this was not significant.
Effect of demographic variables
In the control group, there was no correlation between age or
PM delay and receptor binding in any brain area. In cases of
PSP, there was no correlation between M2 or M4 receptor
binding and age, disease duration or PM delay. There was no
difference in binding of M2 or M4 receptors between those
patients noted to have frontal executive dysfunction or
dementia and those without, although numbers where data
were available in each group were small. In cases of LBD and
AD, there were no correlations between M2 or M4 receptors
and age, PM delay or disease duration in the striatum or
pallidum.
PSP
Control
M2 and M4 receptors
M2 receptors (following
addition of dicyclomine) 
Caudate
Putamen
Globus
pallidus
Figure 1 Autoradiography photographs
showing total M2/M4 binding using 3H
AFDX and M2 receptors only, using
dicyclomine to block M4 receptors.
Cholinergic receptors in PSP 573
www.jnnp.com
DISCUSSION
We have shown a reduction in M2 and M4 receptors in the
posterior striatum in PSP.
Although subtypes of muscarinic receptor have not been
previously measured in PSP, two studies using [3H]N-methyl-
scopolamine which binds to all muscarinic receptors, found a
18–30% reduction in the striatum.7 18 By contrast, the total
number of striatal muscarinic receptors measured by [3H]
quinuclidynyl benzilate ([3H]QNB) was similar between con-
trols and patients with PSP.19
The reduced striatal M2 receptor density is likely to reflect
loss of posterior cholinergic interneurones, previously shown in
vitro. Choline acetyltransferase is a marker of cholinergic
neurone integrity and this was reduced by approximately 50%
in the caudate and by 40% in the putamen in nine patients with
PSP compared with controls.19 Another study showed a 50%
reduction in striatal ACh vesicular transporter expression and
choline acetyltransferase activity in 11 cases with PSP.20 This
reduction was more marked in the posterior striatum, as we
found in this study. Interestingly, nerve growth factor receptors
are localised on intrinsic striatal cholinergic neurones21 and
were reduced by 30% in three cases with PSP compared with
controls and patients with PD.21 The percentage reduction in
cholinergic interneurones found by us is less than some
previous reports, probably reflecting the presence of M2
receptors on corticostriatal and thalamic afferents, which are
not known to be affected in PSP.
The posterior striatum, particularly the putamen, is involved
predominantly in motor function and the anterior striatum and
most of the caudate in cognitive and associative functions.22
Posterior striatal neuronal loss suggests cholinergic dysfunction
may be involved in motor as well as cognitive impairment,
although cholinergic loss in the basal forebrain system may be
more relevant to the cognitive deficits in PSP.
M4 receptors are predominantly located postsynaptically, on
medium spiny neurones of the direct pathway and colocalise
with D1 receptors. They may also be present presynaptically on
striatal cholinergic interneurones,23 and to a lesser extent on
spiny neurones of the indirect pathway.24 The marked reduction
in striatal M4 receptors in our study could indicate loss of
medium spiny projection neurones of the direct pathway,
although D1 receptors were reported to be within the normal
range in one case of PSP.25 Therefore, M4 receptor loss may be
selective or, more likely, represent the loss of cholinergic
interneurones. It is possible that the M4 receptors are down
regulated, although this is unlikely as the reduction in ACh
should, if anything, cause upregulation in functioning neu-
rones.
Gamma-aminobutyric acid is the predominant neurotrans-
mitter in the GP and cholinergic inputs to this nucleus are
modest, as reflected by low overall binding in controls. The
normal, or even increased, M4 receptor binding is supported by
a previous study which measured total muscarinic receptors in
Figure 2 M2 and M4 receptors.
Table 4 M4 receptor binding in the anterior and posterior
striatum
M4 anterior
M4 posterior Control PSP LBD AD
Caudate 59.7 (0.1) 47.3 (0.3) 62.6 (0.2) 54.7 (0.2)
62.8 (0.1) 30.7 (0.4)1 62.7 (0.2) 54.4 (0.2)
Putamen 56.8 (0.1) 43.4 (0.4) 56.3 (0.2) 48.5 (0.2)
52.5 (0.2) 33.8 (0.3)*` 54.8 (0.2) 45.5 (0.2)
GPe 4.1 (0.3) 5.7 (0.4) 6.3 (0.3) 7.4 (0.2)
3.7 (0.3) 4.4 (0.2) 5.7 (0.2) 5.0 (0.3)
GPi 6.3 (0.2) 10.4 (0.1) 3.6 (0.6) 3.6 (0.7)
Insular cortex 28.1 (0.1) 23.6 (0.4) 31.0 (0.4) 24.9 (0.2)
26.8 (0.2) 17.9 (0.3)*1 32.0 (0.1) 23.9 (0.2)
AD, Alzheimer’s disease; GPe, external globus pallidus; GPi, internal globus
pallidus; LBD, Lewy body dementia; PSP, progressive supranuclear palsy.
Values expressed as geometric means (standard deviation) in fmol/mg.
Values in bold indicate M4 receptor binding in anterior striatum.
*Disease vs control p,0.05.
Disease vs control p,0.001.
`PSP vs LBD, p,0.05.
1PSP vs LBD, p,0.001.
PSP vs AD, p,0.01.
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the globus pallidus and found a marked increase in GPi in
patients with PSP.7 Pathologically the GPe and GPi both show
evidence of atrophy and typical PSP pathology.26 27 M4 receptors
may, therefore, be upregulated in the GP in response to
neuronal loss as a compensatory mechanism.
Reduced M2 receptor binding in the insular cortex suggests
decreased cholinergic input. The insular cortex has been
implicated in many functions including somatosensory,28 29
gustatory,29 30 vestibular-like functions and cardiovascular dis-
turbances,29 but none of these symptoms are prominent in PSP.
Failure to detect any difference in receptor binding between
those cases with PSP who are with and without cognitive
impairment may be due to the fact that this information was
available only for a small number of cases.
The normal M2 and M4 receptor binding in the striatum in
LBD suggests cholinergic interneurones and medium spiny
projection neurones of the direct pathway are intact. This is
supported by previous work showing normal striatal M2/M431
and D1 receptors in DLB.32 Medium spiny neurones of the
indirect pathway may be reduced, however, reflected by
decreased numbers of striatal M1 and D2 receptors.31
The increase in M2 binding in the insular cortex of cases with
LBD and AD was not expected as cholinergic cortical projec-
tions are reduced in these dementing illnesses.33 34 However, an
increase in presynaptic receptors has been shown previously in
AD35 and may be due to axonal sprouting of the remaining
cholinergic neurones.
The reduction in posterior striatal M2 in AD may represent a
reduction in cortical afferents rather than a reduction in
intrinsic cholinergic neurones. Normal striatal M4 receptors in
AD suggest medium spiny projection neurones are preserved.
This is supported by a previous study, although muscarinic
subtypes were not measured.31
In conclusion, this study highlights differences in cholinergic
dysfunction between the three disease groups, and is compa-
tible with marked striatal cholinergic pathology in PSP.
Potential therapeutic approaches suggested by our findings
include specific targeting of the remaining M2 receptors with
an M2 antagonist, or use of an M1 agonist to stimulate intact
postsynaptic receptors. The striatum, however, is only part of
the basal ganglia–thalamo–cortico loop and dysfunction of
other sites and neurotransmitter systems are likely to be
clinically relevant.
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